Patients with metastatic renal cell carcinoma staged pT1-4 Nx M1 were enrolled ... ultrasonic examinations and bone scintigraphy before and 12 week after the first immunization.

IT IS well known that metastasis from a carcinoma of the kidney may occur many years after removal of the primary tumor. 1 2 3 The following example is reported because of the extraordinary ...

Proactive onco-coaching did not improve quality of life but was linked to better overall survival in patients with metastatic ...

Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a case-based session ...

Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center and director of the University ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients ... can cause decreased renal function, the US Food and Drug ...

Opdivo plus Cometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.

Studied in combination with Opdivo, Cabometyx saw RCC patients surviving 11 months longer than Sunitinib patients.